Enliven reports Phase 1 CML data for ELVN-001, aligns with FDA on Phase 3 design
The company said it plans to start the Phase 3 ENABLE-2 trial in the second half of 2026 after positive Phase 1 results and FDA discussions.
SEC filing
Latest
1 story
Sign in